Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT06037941
Official study title

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Study summary

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedE-Nose testing and Research blood

The study team can explain what participation involves.

Who it may be forMesothelioma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 24, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Not applicable
Sponsor
Memorial Sloan Kettering Cancer Center
Interventions being studied
Diagnostic Test: E-Nose testing; Diagnostic Test: Research blood
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Mesothelioma→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Aged 30-85 years
  • No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)
  • Recent diagnosis of MPM
  • Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection
Reasons someone may not be able to joinExclusion criteria
  • Aged \<30 or \>85 years at the first outpatient visit
  • History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Memorial Sloan Kettering Basking Ridge (Consent Only)Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Consent Only)Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Consent Only )Montvale, New Jersey
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent Only)Commack, New York
  • Memorial Sloan Kettering Westchester (Consent Only)Harrison, New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York
  • Memorial Sloan Kettering Nassau (Consent Only)Uniondale, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 24, 2026. Always confirm current availability with the study team.

View original record ↗